A mouse study links stress-related hormone signaling to slower gut movement. Understand the BDNF-TrkB pathway and the limits of the findings.
On October 21, 2026, ASBMB Today reported that mouse experiments linked increased stress-related glucocorticoid signaling to weaker BDNF-TrkB activity in the gut’s nervous system and slower gut movement. The research was published in the Journal of Biological Chemistry.
The study did not introduce the idea that stress affects digestion. ASBMB places the work alongside established observations that stress can change gastrointestinal motility, the movement of material through the digestive tract. The new question concerned the biological signals connecting those events.
According to the report, previous research had linked stress and BDNF in the central nervous system. It also pointed to a genetic association between Bdnf and altered stool frequency. Those observations provided background for investigating BDNF-related signaling within the gut itself.
These earlier findings addressed different questions. An association with stool frequency is not the same as showing how a signaling pathway affects gut movement. Likewise, evidence involving the central nervous system does not by itself explain what happens within the gut’s own nerve network.
That local network is called the enteric nervous system, or ENS. ASBMB describes it as the gut’s own regulatory network. Coauthor Srinivas N. Puttapaka described it as the second-largest nervous system in mammals.
The earlier scientific picture therefore already included stress and altered movement. This study added a more specific question: could reduced BDNF-TrkB signaling within the ENS help explain slower motility under stress-related conditions?
For context on the outcome being studied, DigestGenius’s resource on intestinal movement and transit explains the terminology behind motility research.
ASBMB identifies Jared Slosberg of Johns Hopkins School of Medicine and Srinivas N. Puttapaka of Harvard Medical School as coauthors. The report says the research was conducted in the Subhash Kulkarni lab.
The central finding concerned a pathway involving BDNF and TrkB. These names identify parts of the signaling system the researchers investigated. Glucocorticoid signaling was the stress-related hormonal component connected to changes in that system.
ASBMB describes the mouse findings in this order:
The important change in understanding is the level of detail. “Stress affects the gut” is a broad observation. Identifying a particular signaling pathway gives researchers a more focused explanation to investigate.
It also directs attention toward the gut’s own nervous system. In this account, the connection involves more than a general relationship between emotional state and digestive symptoms. The researchers identified changes in a local biological pathway alongside changes in movement.
This places the finding within the wider subject of how nerves and hormones coordinate digestive function. The study’s contribution is a specific candidate mechanism within that larger system.
The researchers then used a TrkB agonist to reactivate the pathway. An agonist is a substance that activates a target. ASBMB reports that this intervention significantly improved gut motility in mice with stress-associated constipation.
The report also says the agonist could bypass the need for the mice’s own BDNF. That detail matters because the earlier observation involved reduced BDNF expression. The intervention tested whether activating the pathway despite that reduction would improve movement.
Puttapaka said reduced BDNF levels in stressed mice with slowed motility motivated this experiment. He described the result as functional evidence that BDNF-TrkB may regulate stress-associated gastrointestinal dysmotility, meaning altered gut movement.
There is an important difference between observing a change and experimentally acting on it. The first part of the work linked reduced signaling with slower motility. The agonist experiment then showed improved motility after the pathway was reactivated in the mouse model.
That makes the result more informative than a report that BDNF levels simply changed during stress. It connects a proposed mechanism to a measured functional outcome in the experimental setting.
Puttapaka also interpreted the findings as showing how psychological stress can have real physical effects on the gut. He used that point to challenge the stigma that these disorders are “only” psychosomatic.
The useful distinction is not between an emotional explanation and a biological one. In the researchers’ interpretation, stress-related signaling and physical changes belong within the same account. Describing a stress connection should not be a way of dismissing digestive symptoms.
The findings are promising as a biological explanation under investigation. Their practical meaning depends on keeping the experimental result separate from claims the report does not support.
The central limitation is the evidence level. ASBMB describes mouse experiments and supplies no human clinical outcomes. The result is not evidence that a TrkB agonist treats constipation in people.
The report presents pathway reactivation as a possible therapeutic lead. It does not describe a human treatment or clinical trial arising from this finding. Nor does it report an approved therapy based on the work.
That distinction sets the boundary for interpreting the intervention. A successful experiment in an animal model is a research result, not a personal treatment recommendation.
The ASBMB report does not provide sample sizes or mouse strains. It also omits doses and treatment durations, along with the specific tests used to measure motility. Numerical effect sizes and detailed statistical values are absent.
Those omissions prevent readers from judging the size and durability of the reported response. The description “significantly improved” does not tell us how much movement changed or how long the improvement lasted.
The source is also a news report about the research rather than a full experimental account. It supplies no independent replication. Its references to earlier stress and BDNF research do not include the underlying studies or quantify those associations.
These are limitations of what can be assessed from the report. They should not be converted into assumptions that the effect was either large or small.
The report does not establish that a particular diet or supplement activates this pathway. It also does not establish that a stress-management practice or microbiome intervention produces the reported effect.
Likewise, the mechanism is not a way to identify the cause of an individual person’s constipation. Recognizing a possible biological connection is different from determining why a particular person has symptoms.
For personal decisions about constipation or changes to care, the appropriate discussion is with a qualified healthcare professional. An experimental pathway should not be used to select a treatment independently.
The researchers’ stated next steps are focused on understanding the biology more precisely. According to ASBMB, they plan to examine:
These questions show where the research is heading. Identifying the relevant nerve populations would make the proposed mechanism more specific. Studying changes over time would address a different question from observing a response during the reported experiment.
The planned work in other gastrointestinal disorders is also a question for investigation, not an extension of the current result. The pathway’s role needs to be established in each setting rather than assumed from shared symptoms.
For readers making everyday food choices, the practical response is to keep the evidence matched to the decision. A finding about molecular signaling belongs in an explanation of gut biology. Evidence supporting a food or supplement choice needs to address that food or supplement and a relevant outcome.
The same standard applies when a health claim borrows the name of a pathway. Shared terminology is not enough to connect a product with an experimental result. Asking what was actually tested is more useful than choosing foods around a molecule mentioned in a headline.
This study gives the stress-gut connection a more specific biological focus. Its realistic contribution to daily life is better understanding, not a reason to restrict meals or add a pathway-targeting supplement.
A molecular explanation for slower gut movement answers a different question from whether a food or supplement has a proven benefit. DigestGenius addresses that gap through free articles and detailed resources on digestion and nutrition, helping adults judge the strength of gut-brain findings before treating an experimental result as settled health guidance.
DigestGenius publishes research-led guidance on digestion, the gut microbiome, fiber, probiotics, gut-brain signaling, inflammation and everyday digestive wellbeing.
Explore clear, research-led guidance on digestion, the microbiome, food, fiber, probiotics and the gut-brain connection.
read the blog
